HOME >> BIOLOGY >> NEWS
Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage

La Jolla, CA, November 9, 1998 - Idun Pharmaceuticals, Inc. today presented data on the cellular mechanism causing cell death during liver transplantation surgery at the American Association for the Study of Liver Diseases meeting in Chicago, IL. The research, titled "Selective Apoptosis of Sinusoidal Endothelial Cells Occurs During Ischemia/Reperfusion Injury of the Liver by a Caspase-Dependent Mechanism," was described in an oral presentation by Shiho Natori, M.D., of the Mayo Clinic in Rochester, MN and was co-authored by researchers at the Mayo Clinic and Idun.

In liver transplantation, the organ is temporarily deprived of oxygen while it is in transit between the donor and recipient. This deprivation is known as ischemia. Upon attachment to the recipient's circulatory system, blood and oxygen flow to the liver is re-established, a process known as reperfusion. While researchers have known that the ischemia/reperfusion, which occurs during transplantation, results in cell damage, the molecular pathway responsible for the damage had not been identified.

"Liver preservation injury is an important problem in transplantation surgery, but without a clear understanding of the mechanisms involved in the process we have not been able to prevent it or reduce its effects," said Karen Valentino, Ph.D., Director of Clinical Development at Idun and co-author on the paper. "These data show that liver ischemia/reperfusion injury induces a caspase-dependent apoptosis in endothelial cells. Now that we have identified which caspase is involved and which cell type is affected, we have the potential to develop therapies to intervene in the process and provide recipients with healthier livers."

Caspases are proteins that are known to play a role in programmed cell death (apoptosis). Researchers used a cell-based assay in combination with high-powered microscopy to detect apoptotic cells and to identify the type of affected cells in liver tissue sections. The
'"/>

Contact: Amy Flood
a.flood@noonanrusso.com
415-677-4455 x.211
Noonan/Russo Communications
9-Nov-1998


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
5. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
6. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
7. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents
8. Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure Of Hepatitis C Helicase Enzyme; Report In Structure
9. Pharmaceuticals Manufactured In Insect Larvae
10. UCSF Team Identifies Two Key Molecules In Asthma; Important Finding For New Therapies That Treat Disease At Cell Level
11. Leading HIV Researcher Identifies Molecular Mechanism That Enhances NaturalImmune Defense Against HIV Infection

Post Your Comments:
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... world,s most popular fruit, can be made both better-tasting ... varieties. , "Working with GM tomatoes that are ... a specific compound, allows us to pinpoint exactly how ... from the John Innes Centre. , The research could ... and shelf life characteristics because even higher levels of ...
(Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
Breaking Biology News(10 mins):Please do try this at home 2The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Vestiage, ... lifestyle company focused on science-based research and development, ... anti-aging cosmeceuticals and nutraceuticals, announced today that it ... States for the sale of Reluma Skin Illuminating ... packet and application by sending an email to ...
(Date:5/23/2013)...  BioScrip, Inc. (NASDAQ: BIOS ) today ... 2013 Global Healthcare Conference to be held June 3-6, ... Richard Smith , President and Chief ... Chief Financial Officer, will present on Monday, June 3, ... About BioScrip BioScrip, Inc. provides comprehensive infusion ...
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
Cached News: